Immunogenicity and safety of live attenuated varicella vaccine in 12 and 18 month-old children, with and without concomitant administration of measles-mumps-rubella [MMR] vaccine

Trial Profile

Immunogenicity and safety of live attenuated varicella vaccine in 12 and 18 month-old children, with and without concomitant administration of measles-mumps-rubella [MMR] vaccine

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary) ; Measles mumps and rubella virus vaccine; MMR-varicella zoster virus vaccine
  • Indications Chickenpox; Measles; Mumps; Rubella
  • Focus Pharmacodynamics
  • Most Recent Events

    • 27 Apr 2010 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
    • 26 Jul 2007 Status changed from recruiting to discontinued.
    • 16 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top